FDA’s New Transparency Initiative
FDA's New Transparency Initiative
The U.S. Food and Drug Administration (FDA) has released over 200 Complete Response Letters (CRLs) from 2020–2024, providing unprecedented insight into its drug and biological product approval process. This initiative enhances transparency, offering drug developers and the public a clearer understanding of FDA decisions to foster predictability and accelerate innovative treatments. At EOSPA we can help navigate these complexities, ensuring your application addresses FDA concerns effectively.
Key Areas Cited in CRLs:
-
Safety Concerns: Issues related to potential risks or adverse effects of the drug or biological product.
-
Efficacy Deficiencies: Insufficient evidence demonstrating the product’s effectiveness for its intended use.
-
Manufacturing Issues: Problems with production processes, quality control, or facility compliance.
-
Bioequivalence Problems: Challenges in proving the product matches the performance of a reference drug.
-
Incomplete Application Data: Missing or inadequate information required for FDA approval.